Drug profile · INN
covid-19 mrna vaccine
COMIRNATY
covid-19 mrna vaccine (COMIRNATY) is a spike glycoprotein vaccine antigen. Associated with Teva Pharma GmbH.
EMA: approved Antiinfectives for systemic use (J07) J07BN01
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — covid-19 mrna vaccine
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
covid-19 mrna vaccine (COMIRNATY) is a spike glycoprotein vaccine antigen. Associated with Teva Pharma GmbH.
Key facts
INN covid-19 mrna vaccine
Brand COMIRNATY
Mechanism Spike glycoprotein vaccine antigen
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BN01
Originator Teva Pharma GmbH
Mechanism of action
Spike glycoprotein vaccine antigen
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is covid-19 mrna vaccine?
covid-19 mrna vaccine (COMIRNATY) is a spike glycoprotein vaccine antigen. Associated with Teva Pharma GmbH.
What is the brand name for covid-19 mrna vaccine?
COMIRNATY is a marketed brand name for covid-19 mrna vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.